US Patent

US8613950 — Pharmaceutical forms with improved pharmacokinetic properties

Formulation · Assigned to Bayer Intellectual Property GmbH · Expires 2028-12-23 · 3y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects novel drug formulations of vardenafil that dissolve rapidly in the mouth and have improved pharmacokinetic properties.

USPTO Abstract

The present application relates to novel drug formulations of vardenafil which dissolve rapidly in the mouth and lead to increased bioavailability and to a plateau-like plasma concentration profile, and to processes for their preparation.

Drugs covered by this patent

vardenafil-hydrochloride (VARDENAFIL HYDROCHLORIDE)

Patent Metadata

Patent number: US8613950
Jurisdiction: US
Classification: Formulation
Expires: 2028-12-23
Drug substance claim: No
Drug product claim: Yes
Assignee: Bayer Intellectual Property GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.